Table 2.
Office, central, and ABPM blood pressures and medication use in subjects not assuming antihypertensive therapy according to their office and 24 h ABPM BP profile.
| True NT (n = 1721) (group 0) |
WCHT (n = 187) (group 1) |
MH (n = 147) (group 2) |
True HT (n = 907) (group 3) |
ANOVA P value |
Post-hoc Bonferroni (p < 0.05) |
ANCOVA P valuea |
|
|---|---|---|---|---|---|---|---|
| Office SBP (mmHg) | 115.5 ± 10.9 | 145.0 ± 10.9 | 126.6 ± 9.1 | 136.5 ± 17.9 | .0001 | 1 > 3 > 2 > 0 | .0001 |
| Office DBP (mmHg) | 72.7 ± 7.2 | 88.1 ± 7.2 | 75.2 ± 6.3 | 84.0 ± 9.8 | .0001 | 1 > 3 > 2 > 0 | .0001 |
| Office MBP (mmHg) | 86.8 ± 7.6 | 106.9 ± 5.8 | 92.1 ± 6.1 | 101.3 ± 11.3 | .0001 | 1 > 3 > 2 > 0 | .0001 |
| Office PP (mmHg) | 42.8 ± 8.2 | 56.9 ± 13.5 | 51.5 ± 8.6 | 52.5 ± 13.9 | .0001 | 1 > 2,3 > 0 | .0001 |
| HR (bpm) | 68.6 ± 10.8 | 68.7 ± 11.1 | 66.7 ± 9.9 | 69.7 ± 11.3 | .01 | 3 > all | .0001 |
| 24 h SBP (mmHg) | 112.5 ± 6.4 | 117.2 ± 5.1 | 129.3 ± 3.9 | 130.8 ± 9.6 | .0001 | 2,3 > 1 > 0 | .0001 |
| 24 h DBP (mmHg) | 70.5 ± 4.9 | 72.1 ± 4.8 | 74.5 ± 4.2 | 82.9 ± 6.4 | .0001 | 2,3 > 1 > 0 | .0001 |
| Central SBP (mmHg) | 102.7 ± 11.8 | 131.2 ± 11.9 | 113.3 ± 11.3 | 124.3 ± 18.3 | .0001 | 1 > 3 > 2 > 0 | .0001 |
| Central ESP (mmHg) | 94.0 ± 10.9 | 119.1 ± 9.8 | 102.6 ± 10.8 | 113.6 ± 15.7 | .0001 | 1 > 3 > 2 > 0 | .0001 |
| Antidiabetic drugs (%) | 1.9 | 3.7 | 8.2 | 3.5 | .0001 | 2 > all | 0.19 |
| Antiplatelet (%) | 2.5 | 9.1 | 8.2 | 4.6 | .0001 | 0.13 | |
| Statin (%) | 2.3 | 6.4 | 8.9 | 5.1 | .0001 | 2 > all | 0.44 |
| Nitrates (%) | 0.6 | 0.5 | 2.0 | 0.8 | 0.29 | 0.11 |
SBP = Systolic Blood Pressure.
DBP = Diastolic Blood Pressure.
MBP = Mean Blood Pressure.
PP= Pulse Pressure.
HR = Heart Rate.
ESP = End-Systolic Pressure.
a
After controlling for age, sex, BMI, smoking, and diabetes mellitus.